These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 14872419

  • 21. Inhibitor treatment: state of the art.
    Shapiro A.
    Dis Mon; 2003 Jan; 49(1):22-38. PubMed ID: 12525826
    [Abstract] [Full Text] [Related]

  • 22. Recombinant factor VIIa. An update on its clinical use.
    Franchini M, Zaffanello M, Veneri D.
    Thromb Haemost; 2005 Jun; 93(6):1027-35. PubMed ID: 15968384
    [Abstract] [Full Text] [Related]

  • 23. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.
    Mohr AM, Holcomb JB, Dutton RP, Duranteau J.
    Crit Care; 2005 Jun; 9 Suppl 5(Suppl 5):S37-42. PubMed ID: 16221318
    [Abstract] [Full Text] [Related]

  • 24. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
    Croom KF, McCormack PL.
    BioDrugs; 2008 Jun; 22(2):121-36. PubMed ID: 18345709
    [Abstract] [Full Text] [Related]

  • 25. rFVIIa and NN1731 reduce bleeding in hydroxyethyl starch hemodiluted rabbits.
    Lauritzen B, Viuff D, Tranholm M, Ezban M.
    J Trauma; 2010 Nov; 69(5):1196-202. PubMed ID: 20032791
    [Abstract] [Full Text] [Related]

  • 26. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
    Smith OP.
    Pathophysiol Haemost Thromb; 2002 Nov; 32 Suppl 1():22-5. PubMed ID: 12214142
    [Abstract] [Full Text] [Related]

  • 27. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
    Allen GA, Hoffman M, Roberts HR, Monroe DM.
    Can J Anaesth; 2002 Dec; 49(10):S7-14. PubMed ID: 12546000
    [Abstract] [Full Text] [Related]

  • 28. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
    Petrini P, Klementz G.
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
    [Abstract] [Full Text] [Related]

  • 29. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors.
    Seremetis S.
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S29-30. PubMed ID: 14567532
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G, Shafer FE, Rojas P, Seremetis S.
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U, Lee CA.
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [Abstract] [Full Text] [Related]

  • 35. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
    He S, Blombäck M, Jacobsson Ekman G, Hedner U.
    J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322
    [Abstract] [Full Text] [Related]

  • 36. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
    Young G, Cooper DL, Gut RZ, HTRS Investigators.
    Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
    [Abstract] [Full Text] [Related]

  • 37. Single-dose recombinant activated factor VII therapy in hemophilia patients with inhibitors.
    Kenet G, Martinowitz U.
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S38-41. PubMed ID: 18544424
    [Abstract] [Full Text] [Related]

  • 38. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A.
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [Abstract] [Full Text] [Related]

  • 39. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
    Łaguna P, Mital A.
    Adv Clin Exp Med; 2012 Oct; 21(4):519-24. PubMed ID: 23240458
    [Abstract] [Full Text] [Related]

  • 40. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
    Joshi AV, Stephens JM, Munro V, Mathew P, Botteman MF.
    Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.